0B68 Aplin, Andrew E. - Thomas Jefferson University - Thomas Jefferson University
aea004

Andrew E. Aplin, PhD

Contact Dr. Aplin

Kimmel Cancer Center
233 S. Tenth Street, Suite 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor
  2. Resistance to RAF inhibitors revisited
  3. FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma
  4. Unmet needs in melanoma research
  5. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma
  6. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors
  7. Erratum: Hippo: Hungry, hungry for melanoma invasion (Journal of Investigative Dermatology)
  8. Hippo: Hungry, hungry for melanoma invasion
  9. Adaptive resistance to RAF inhibitors in melanoma
  10. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma
  11. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors
  12. A statement on vemurafenib-resistant melanoma
  13. Meeting report: The future of preclinical mouse models in melanoma treatment is now.
  14. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
  15. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
  16. Meeting report: The future of preclinical mouse models in melanoma treatment is now
  17. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells
  18. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor
  19. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
  20. Resistance to Chemotherapy. Short-Term Drug Tolerance and Stem Cell-Like Subpopulations.
0